GlassScriptPhysician profile
Travis D Ewing
NPI 1376980367
$4,020.20
in general payments reported to CMS, 2019-2025
29 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $237 · 2022: $526 · 2023: $981 · 2024: $1,042 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.74 | 2021-2025 | |
| Pfizer INC. | $796.74 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $503.53 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $340.25 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $251.76 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $118.01 | 2020-2024 | Wegovy |
| Abbott Laboratories | $100.02 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $91.79 | 2020-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $71.56 | 2023-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.35 | 2022-2025 | |
| Nevro Corp. | $58.94 | 2022-2023 | Senza |
| Smith+Nephew, INC. | $53.05 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $45.54 | 2022 | |
| Shield Therapeutics INC | $43.86 | 2024-2025 | |
| Medtronic, INC. | $41.00 | 2024 | Intellis Adaptivestim |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.66 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $32.61 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $31.17 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $30.06 | 2025 | Voquezna |
| Genzyme Corporation | $20.11 | 2024 | |
| Dexcom, INC. | $18.75 | 2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $18.52 | 2025 | Sapien 3 Ultra Resilia |
| Exeltis, USA INC. | $18.23 | 2023 | Slynd |
| Organon LLC | $17.85 | 2025 | Nexplanon |
| Upsher-Smith Laboratories LLC | $14.90 | 2020 | |
| Genentech USA, INC. | $13.47 | 2020 | |
| Amarin Pharma, INC. | $12.68 | 2020 | |
| Paratek Pharmaceuticals, INC. | $12.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.